MaxCyte, Inc. Annual Report (7254C)
June 19 2019 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7254C
MaxCyte, Inc.
19 June 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
2018 Annual Report
Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based medicines and life sciences company,
announces that copies of the 2018 Annual Report and Accounts have
been sent to Stockholders and are available on the "Investors"
section of the Company's website at www.maxcyte.com.
MaxCyte also announces that its Annual General Meeting of
Stockholders is planned to be held on 31 October 2019. Formal
notice and resolutions, along with the Annual Meeting Proxy Card,
will be circulated in September 2019 to Stockholders of record at
that time.
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its flow electroporation instruments worldwide, with all of
the top ten global biopharmaceutical companies. The Company now has
more than 70 partnered program licenses in cell therapy with more
than 35 licensed for clinical use, including four announced
commercial licenses covering potentially more than 30 products with
aggregate potential milestones of more than $250M. With its robust
delivery technology platform, MaxCyte helps its partners to unlock
the full potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSGUGDLXUBBGCC
(END) Dow Jones Newswires
June 19, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024